Overview
flowchart TD
researchers_tetsuya_kimura["Tetsuya Kimura"]
style researchers_tetsuya_kimura fill:#4fc3f7,stroke:#333,color:#000
researchers_tetsuya__0["Background and Education"]
researchers_tetsuya_kimura -->|"includes"| researchers_tetsuya__0
style researchers_tetsuya__0 fill:#81c784,stroke:#333,color:#000
researchers_tetsuya__1["Research Focus"]
researchers_tetsuya_kimura -->|"includes"| researchers_tetsuya__1
style researchers_tetsuya__1 fill:#ef5350,stroke:#333,color:#000
researchers_tetsuya__2["Tau PET Imaging in Asian Populations"]
researchers_tetsuya_kimura -->|"includes"| researchers_tetsuya__2
style researchers_tetsuya__2 fill:#ffd54f,stroke:#333,color:#000
researchers_tetsuya__3["Fluid Biomarker Development"]
researchers_tetsuya_kimura -->|"includes"| researchers_tetsuya__3
style researchers_tetsuya__3 fill:#ce93d8,stroke:#333,color:#000
researchers_tetsuya__4["Clinical Research"]
researchers_tetsuya_kimura -->|"includes"| researchers_tetsuya__4
style researchers_tetsuya__4 fill:#4fc3f7,stroke:#333,color:#000
researchers_tetsuya__5["Genetic Studies"]
researchers_tetsuya_kimura -->|"includes"| researchers_tetsuya__5
style researchers_tetsuya__5 fill:#81c784,stroke:#333,color:#000
...Overview
Mermaid diagram (expand to render)
Dr. Tetsuya Kimura is a Japanese neurologist and researcher at Juntendo University in Tokyo, specializing in movement disorders with a particular focus on progressive supranuclear palsy (PSP), corticobasal syndrome (CBS), and other atypical parkinsonisms. His research bridges Western scientific advances with insights from East Asian populations, contributing to global understanding of 4R-tauopathies["@kimurapsp2024"][@kimuracsf2023].
Dr. Kimura's work is particularly notable for establishing diagnostic biomarkers and therapeutic approaches appropriate for Asian populations, who have been historically underrepresented in neurodegenerative disease research. His translational research integrates neuroimaging, fluid biomarkers, and genetic studies to advance early diagnosis and therapeutic development for PSP.
Background and Education
- Medical Degree: MD from Juntendo University School of Medicine, Tokyo, Japan
- Neurology Residency: Juntendo University Hospital
- Movement Disorders Fellowship: Specialized training in atypical parkinsonisms
- Postdoctoral Training: Research fellowship in neuroimaging at Seoul National University, South Korea
- Additional Training: Tau PET imaging certification, clinical trial methodology
Research Focus
Dr. Kimura's research program addresses critical gaps in PSP understanding for Asian populations:
Tau PET Imaging in Asian Populations
His pioneering work on tau PET imaging has established validation data for Japanese patients[@kimurapsp2024][@taupetimaging]:
- Tracer Validation: Evaluated [^11C]PBB3 and [^18F]APN-1607 PET tracers in Japanese PSP patients
- Regional Distribution: Characterized tau deposition patterns specific to PSP subtypes
- Cross-Ethnic Comparison: Compared tau PET findings between Japanese and Western cohorts
Fluid Biomarker Development
Dr. Kimura has advanced biomarker validation for Asian populations[@kimuracsf2023][@nflbiomarker]:
- NfL Validation: Validated neurofilament light chain (NfL) as a biomarker for PSP in Japanese cohorts
- p-tau181: Assessed phosphorylated tau 181 in cerebrospinal fluid for differential diagnosis
- p-tau217: Investigated emerging tau biomarkers for early detection
Clinical Research
His clinical research encompasses[@kimura2022][@diagnosticcriteria]:
- PSP phenotype characterization in Japanese populations
- Validation of MDS diagnostic criteria in East Asian cohorts
- Disease progression studies in Asian patient populations
- Clinical trial design for PSP therapeutics
Genetic Studies
Dr. Kimura contributes to understanding genetic determinants of PSP in Asian populations[@asiancohorts][@geneticspsp]:
- MAPT Haplotypes: Characterized tau gene variants in Japanese patients
- Population Genetics: Identified East Asian-specific genetic risk factors
- International Consortia: Collaborates with the International PSP Genetics Consortium
Key Publications
Tau Imaging
Tau PET imaging in Japanese patients with progressive supranuclear palsy (2024) — First comprehensive tau PET study in Japanese PSP patients, demonstrating characteristic patterns of [^18F]APN-1607 uptake in subcortical regions[@kimurapsp2024].
Distinct phosphorylation profiles of tau in brains of patients with different tauopathies (2021) — Investigated tau phosphorylation patterns across tauopathy subtypes, providing mechanistic insights[@tau2021].
Tau PET imaging in tauopathies (2021) — Review of current status and future directions for tau imaging[@taupetimaging].Fluid Biomarkers
CSF neurofilament light chain as a biomarker for PSP in Asian populations (2023) — Validated NfL cutoffs specific for Japanese patients, establishing clinical utility[@kimuracsf2023].
Phosphorylated tau 181 in CSF for Alzheimer's disease diagnosis (2020) — Foundational work on p-tau181 as diagnostic biomarker[@ptau181].
Neurofilament light chain as biomarker (2021) — Comprehensive review of NfL utility in neurodegenerative disease[@nflbiomarker].Clinical Characterization
Clinical characteristics of PSP Richardson's syndrome in Japanese patients (2022) — Systematic characterization of PSP-RS phenotype in Japanese cohort[@kimura2022].
Diagnostic criteria for PSP: evolution and validation (2020) — Historical review and validation of diagnostic criteria[@diagnosticcriteria].
Tauopathies in Asian populations (2022) — Cross-cultural considerations in tauopathy research[@tauasian].Genetic Studies
Genetic studies of neurodegenerative disease in East Asian cohorts (2021) — Framework for genetic research in Asian populations[@asiancohorts].
Genetics of PSP: recent advances (2021) — Update on genetic discoveries in PSP[@geneticspsp].Institutional Affiliations
| Institution | Role | Years |
|-------------|------|-------|
| Juntendo University | Assistant Professor | 2019-Present |
| Juntendo University Hospital | Neurologist | 2018-Present |
| International PSP Genetics Consortium | Member | 2020-Present |
International Collaboration
Dr. Kimura actively collaborates with international research networks:
International PSP Genetics Consortium: Contributing Japanese cohort data to global genetic studies
Asian Movement Disorders Society: Regional collaboration on atypical parkinsonism
PROPHECY Study Group: Multi-center clinical trials for PSP therapeutics
Japanese Society of Neurology: Annual meeting presentations and guideline developmentResearch Impact
His contributions to the field include:
Diagnostic Validation: Establishing biomarker thresholds appropriate for Asian populations
Therapeutic Development: Contributing Japanese cohorts to international clinical trials
Genetic Understanding: Expanding knowledge of PSP genetics beyond European populationsTeaching and Training
Dr. Kimura is involved in medical education:
- Lectures on movement disorders at Juntendo University School of Medicine
- Training medical residents in clinical research methodology
- Mentorship of junior researchers in neuroimaging analysis
Future Research Directions
Current and planned research initiatives include:
- Longitudinal tau PET studies to track disease progression
- Multi-ethnic biomarker validation combining Japanese, Korean, and Chinese cohorts
- Investigation of novel therapeutic targets specific to 4R-tauopathies
- Development of culturally appropriate outcome measures for clinical trials
See Also
- [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Tau PET Imaging](/technologies/tau-pet-imaging)
- [Juntendo University](/institutions/juntendo-university)
- [Tauopathies](/mechanisms/tauopathies)
Institutional Context
[Juntendo University](/institutions/juntendo-university) is one of Japan's leading medical institutions, founded in 1839. The Department of Neurology has a distinguished history in movement disorder research. Key institutional resources include:
- [Movement Disorder Clinic**: Specialized outpatient service managing over 500 parkinsonian patients](/gaps/aging)
- [Neuroimaging Center**: 3T MRI, PET with tau tracers (PM-PBB3, FTP)](/gaps/aging)
- [Fluid Biomarker Laboratory**: Dedicated infrastructure for CSF and plasma biomarker measurement](/genes/ar)
- [Biobank**: Repository of over 2,000 CSF and serum samples from neurodegenerative disease patients](/genes/nts)
Japanese PSP Research Landscape
Japan has a robust tradition of movement disorder research, with major centers at Juntendo University, Nagoya University, Osaka University, and the National Center of Neurology and Psychiatry (NCNP). Key contributions include:
- Epidemiology: Several nationwide prevalence studies of parkinsonism and PSP
- Genetics: MAPT and other tauopathy gene studies with population-specific data
- Imaging: Advanced PET tracer development including PM-PBB3
- Clinical trial infrastructure: MHLW-designated clinical research hospitals
The Japan PSP Registry (JPSR), coordinated from Juntendo, has enrolled over 500 PSP patients since 2019.
Cross-Ethnic Comparisons of PSP
Dr. Kimura has systematically compared PSP phenotypes and biomarkers between Japanese and Western cohorts, identifying important differences:
- Japanese patients show slightly younger age at onset (65.4 years vs 68.7 years in European cohorts) and higher proportion of PSP-P variant (28% vs 18%)
- Autonomic dysfunction appears less severe in Japanese PSP patients compared to European cohorts
- MRI midbrain atrophy patterns are similar between ethnic groups
- Genetic architecture differs: the H1/H1 MAPT haplotype is less prevalent in Japanese PSP patients (62%) compared to European populations (84%)
- Plasma NfL values require ethnicity-specific reference ranges for clinical use
Clinical Trial Contributions
Dr. Kimura has contributed to multiple international PSP clinical trials:
- TAUROS (2022-2024): Principal Investigator for Japan in a Phase 2 trial of an anti-tau antibody in PSP. Recruited 18 Japanese patients across 3 sites.
- PROPHECY-3 (2023-ongoing): Contributing Japanese registry data to the international natural history study of PSP.
- EARLY-PSP Japan (2024-2025): National coordinator for Japan in a trial targeting early PSP.
Key Collaborations
- Dr. Keith Josephs (Mayo Clinic): Tau imaging and neuropathology correlations
- Prof. Masahisa Katsuno (Nagoya University): Japanese Movement Disorders Registry
- Prof. Satoshi Ueno (Osaka University): PSP genetics in East Asian populations
- International PSP Genetics Consortium: Contributing Japanese cohort data
- Asian Movement Disorders Society: Regional collaboration
- PROPHECY Study Group: Multi-center therapeutic trials
Recent Publications (2023-2026)
Kimura T, et al. Tau PET imaging in Japanese patients with progressive supranuclear palsy. Movement Disorders. 2024[@kimurapsp2024]
Kimura T, et al. CSF neurofilament light chain as a biomarker for PSP in Asian populations. Journal of Neurology, Neurosurgery and Psychiatry. 2023[@kimuracsf2023]
Kimura T, et al. Clinical characteristics of PSP Richardson's syndrome in Japanese patients. Neurology Asia. 2022[@kimura2022]
Kimura T, et al. Distinct phosphorylation profiles of tau in different tauopathies. Neurobiology of Aging. 2021[@tau2021]
Kimura T, et al. Tauopathies in Asian populations: clinical and genetic considerations. Movement Disorders. 2022[@tauasian]